A randomized phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer: Short-term infusion versus protracted infusion chemotherapy (KROSG0101/JROSG021).

@article{Nishimura2009ARP,
  title={A randomized phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer: Short-term infusion versus protracted infusion chemotherapy (KROSG0101/JROSG021).},
  author={Yasumasa Nishimura and Michihide Mitsumori and Masahiro Hiraoka and Ryuta Koike and Kiyoshi Nakamatsu and Masashi Kawamura and Yoshiharu Negoro and Kazuhisa Fujiwara and Hideyuki Sakurai and Norio Mitsuhashi},
  journal={Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology},
  year={2009},
  volume={92 2},
  pages={260-5}
}
PURPOSE A randomized phase II study was conducted to compare the toxicity and efficacy of combining short-term chemotherapy (CT) or protracted CT with radiotherapy (RT) for esophageal cancer. MATERIALS AND METHODS Eligible patients were <75 years and with performance status (PS) of 0-2, and had stages II-IVA esophageal cancer. Two cycles of cisplatin 70 mg/m(2) for 1 day and 5FU 700 mg/m(2) for 5 days (arm A) or cisplatin 7 mg/m(2) for 10 days and 5FU 250 mg/m(2) for 14 days (arm B) were… CONTINUE READING